Impax Laboratories and Dr. Reddy’s have settled their patent infringement dispute over Rytary, a medication used to treat Parkinson’s disease. Walgreens’ three core segments—U.S. pharmacy ...

JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million.

Q4 2024 Management View Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four ...

The drug is capturing market share faster than expected, making up about 15% of Rytary’s volume. Schott anticipates strong growth throughout the year as Amneal expands insurance coverage.

He added that Amneal expects continued top- and bottom-line growth in 2025, despite the loss of exclusivity for Rytary. Amneal projects 2025 total revenue of $3.0B-$3.1B, driven by double-digit ...